News

Micro RNA Molecule miR-146a May Be Useful Diagnostic Marker

A micro RNA molecule called miR-146a was found at high levels in the blood of patients with myasthenia gravis (MG), and this is thought to contribute to disease development, a single-site study suggests. The findings put forward miR-146a as “a suitable candidate marker for diagnosing MG,” the researchers wrote.

MuSK-MG Tied to Poorer Outcomes in Myasthenic Crisis, Study Reports

Patients with myasthenia gravis (MG) and self-reactive antibodies against the muscle-specific kinase (MuSK) protein are more likely to have poorer outcomes when experiencing a myasthenic crisis than other MG patients, a study suggests. Outcomes linked to MuSK antibody production include longer periods of hospitalization or admittance to intensive care,…

Plasma Exchange May Be Safe, Effective as Short-term MG Therapy

A new type of plasma exchange treatment, called double-filtration plasmapheresis (DFPP), may be effective and safe for short-term relief of myasthenia gravis (MG) symptoms, a review study has found. These findings may have important clinical implications, especially for patients with severe or critical MG, the researchers noted. The review,…

Early Swallowing Difficulty Tied to Worse Outcomes

People with myasthenia gravis (MG) who have difficulty swallowing are more likely to have poor clinical outcomes, according to a recent study. Data from the study also indicates that low levels of albumin — a protein found in the blood that helps transporting hormones and other key molecules in…

#AANAM – Study Examines Seronegative Characteristics

Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read stories from the conference. Myasthenia gravis (MG) patients who test negative for the presence of the most common MG self-reactive antibodies (autoantibodies) more…